Advanced in Hysterectomy

Dr. John O. Schorge

Gynecologic Oncology | Obstetrics and Gynecology | Oncology
UT Regional One Physicians Inc
880 Madison Ave, 
Memphis, TN 
Accepting New Patients
Offers Telehealth
Advanced in Hysterectomy
UT Regional One Physicians Inc
880 Madison Ave, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Schorge is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Memphis, Tennessee. Dr. Schorge is rated as an Advanced provider by MediFind in Hysterectomy. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Endometrial Cancer, Hysterectomy, and Bladder Reconstruction. Dr. Schorge is currently accepting new patients.

His clinical research consists of co-authoring 116 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles in the study of Hysterectomy.

Specialties
Gynecologic Oncology
Obstetrics and Gynecology
Oncology
Licenses
Obstetrics & Gynecology in TN
Hospital Affiliations
Regional One Health
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

UT REGIONAL ONE PHYSICIANS INC
880 Madison Ave, Memphis, TN 38103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Afuresertib
Study Phase: Phase 2
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Biological, Drug
Study Drugs: Oregovomab, Paclitaxel, Carboplatin
Study Phase: Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Enrollment Status: Unknown
Publish Date: February 19, 2018
Intervention Type: Other, Behavioral
Study Phase: Phase 3
View 8 Less Clinical Trials

116 Total Publications

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: August 05, 2025
Similar Doctors
Advanced in Hysterectomy
Dr. Sanjeev Kumar
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Hysterectomy
Dr. Sanjeev Kumar
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
6584 Poplar Ave, Ste 400, 
Memphis, TN 
 (11.1 miles away)
901-226-4280
Languages Spoken:
English, Hindi, Punjabi, Sindhi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sanjeev Kumar is a Gynecologic Oncologist and an Oncologist in Memphis, Tennessee. Dr. Kumar is rated as an Advanced provider by MediFind in Hysterectomy. His top areas of expertise are Malignant Mixed Mullerian Tumor, Angiomyoma, Uterine Fibroids, Hysterectomy, and Oophorectomy. Dr. Kumar is currently accepting new patients.

Advanced in Hysterectomy
Dr. Todd D. Tillmanns
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Hysterectomy
Dr. Todd D. Tillmanns
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

The West Clinic, PLLC

7945 Wolf River Blvd, 
Germantown, TN 
 (13.4 miles away)
901-683-0055
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Tillmanns is a Gynecologic Oncologist and an Oncologist in Germantown, Tennessee. Dr. Tillmanns is rated as a Distinguished provider by MediFind in Hysterectomy. His top areas of expertise are Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vulvectomy, and Oophorectomy. Dr. Tillmanns is currently accepting new patients.

Advanced in Hysterectomy
Dr. Serena N. Vance
Obstetrics and Gynecology
Advanced in Hysterectomy
Dr. Serena N. Vance
Obstetrics and Gynecology

St Bernards Physician Clinics Inc

800 S Church St, Suite 302, 
Jonesboro, AR 
 (61.0 miles away)
870-935-3990
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Serena Vance is an Obstetrics and Gynecologist in Jonesboro, Arkansas. Dr. Vance is rated as an Advanced provider by MediFind in Hysterectomy. Her top areas of expertise are Vaginal Bleeding Between Periods, Preeclampsia, Uterine Prolapse, Hysterectomy, and Oophorectomy. Dr. Vance is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schorge's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile